Surrozen (SRZN) Other financing activities (2020 - 2026)

Surrozen (SRZN) posted quarterly Other financing activities of $92000.0 for Q1 2026, up 17.95% quarter-over-quarter from $78000.0 in Q4 2025.

Surrozen (SRZN) Other financing activities (2020 - 2026) Analysis & Trends

Surrozen's Other financing activities history runs 5 years deep, the most recent figure standing at $92000.0 for Q1 2026.

In Q1 2026, Other financing activities changed N/A year-over-year to $92000.0; the TTM figure through Mar 2026 stood at $209000.0 (up 435.9% YoY), while the FY2025 annual figure was $87000.0, up 123.08% from the prior year.
Other financing activities for Q1 2026 stood at $92000.0, up from $78000.0 in the prior quarter.
The five-year high for Other financing activities was $92000.0 in Q1 2026, with the low at $39000.0 in Q4 2024.
The 3-year median for Other financing activities is $78000.0 (2025), against an average of $69666.7.
Peak annual rise in Other financing activities reached 100.0% in 2025, while the deepest fall reached 100.0% in 2025.
Surrozen's Other financing activities stood at $39000.0 in 2024, then surged by 100.0% to $78000.0 in 2025, then climbed by 17.95% to $92000.0 in 2026.
Business Quant data shows SRZN's Other financing activities at $92000.0 in Q1 2026, $78000.0 in Q4 2025, and $39000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Surrozen	281.63 Mn	281.63 Mn	-

Download Data